Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
iX Biopharma Ltd. (SG:42C)
SGX:42C
iX Biopharma Ltd. (42C) Share Price & Analysis
3 Followers
42C Stock Chart & Stats
Day’s RangeS$0 - S$0
52-Week RangeS$0.03 - S$0.06
Previous CloseS$0.03
Volume2.89M
Average Volume (3M)1.60M
Market Cap
S$28.12M
Enterprise ValueS$26.15M
Total Cash (Recent Filing)S$6.21M
Total Debt (Recent Filing)S$4.24M
Price to Earnings (P/E)―
Beta0.45
Next Earnings
Aug 19, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding768,317,356
10 Day Avg. Volume778,790
30 Day Avg. Volume1,595,680
Standard Deviation0.08
R-Squared0.02
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
iX Biopharma Ltd. News
PremiumCompany Announcements
iX Biopharma Expands Capital with New Shares and Warrants
PremiumCompany Announcements
iX Biopharma Ltd Faces Rights Issue Shortfall
PremiumCompany Announcements
iX Biopharma’s Trial Boosts NAD+ and Wellness
PremiumCompany Announcements
iX Biopharma Advances Rights cum Warrants Issue
PremiumCompany Announcements
iX Biopharma Adjusts Convertible Bonds Terms
PremiumCompany Announcements
iX Biopharma Advances in Drug DevelopmentOptions Prices
Currently, No data available
---
Ownership Overview
26.98% Insiders
0.00% Mutual Funds
0.00% Other Institutional Investors
73.02% Public Companies and
Individual Investors
42C FAQ
What was iX Biopharma Ltd.’s price range in the past 12 months?
iX Biopharma Ltd. lowest share price was S$0.03 and its highest was S$0.06 in the past 12 months.
What is iX Biopharma Ltd.’s market cap?
Currently, no data Available
When is iX Biopharma Ltd.’s upcoming earnings report date?
iX Biopharma Ltd.’s upcoming earnings report date is Aug 19, 2024 which is in 23 days.
How were iX Biopharma Ltd.’s earnings last quarter?
iX Biopharma Ltd. released its earnings results on Feb 05, 2024. The company reported -S$0.009 earnings per share for the quarter, missing the consensus estimate of N/A by -S$0.009.
Is iX Biopharma Ltd. overvalued?
According to Wall Street analysts iX Biopharma Ltd.’s price is currently Overvalued.
Does iX Biopharma Ltd. pay dividends?
iX Biopharma Ltd. does not currently pay dividends.
What is iX Biopharma Ltd.’s EPS estimate?
iX Biopharma Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does iX Biopharma Ltd. have?
iX Biopharma Ltd. has 937,347,170 shares outstanding.
What happened to iX Biopharma Ltd.’s price movement after its last earnings report?
iX Biopharma Ltd. reported an EPS of -S$0.009 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of iX Biopharma Ltd.?
Currently, no hedge funds are holding shares in SG:42C
---
iX Biopharma Ltd. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.88%
12-Months-Change
Fundamentals
Return on Equity
-76.96%
Trailing 12-Months
Asset Growth
-29.08%
Trailing 12-Months
Company Description
iX Biopharma Ltd.
iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company focused on the development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. Its products under development are Wafermine and BnoX for pain management, Wafesil for erectile dysfunction, WafeRest for improved sleep quality, and others. Its business segments are Specialty Pharmaceutical and Nutraceutical business segments. The firm's business segments operate in Singapore, Australia, and China, of which the majority of the revenue comes from China..
---
Technical Analysis
---